BioSpace News Archive

Novavax, Inc. announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive allosteric modulator, in adults living with schizophrenia in The Lancet.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin).

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced that its subsidiary WuXi Biologics Co., Ltd. has been removed from the Unverified List by the U.S. Department of Commerce, effective Dec. 16, 2022.

Sosei Group Corporation (“the Company”; TSE: 4565) announces it has entered a drug discovery collaboration with Eli Lilly and Company (“Lilly”), a global biopharmaceutical company, to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with diabetes and metabolic diseases.

The Board of directors of NuGen Medical Devices Inc., a leader in needle-free drug delivery, announces the departure of Mr. Michael Wright, President and Chief Executive Officer, effective immediately.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share.